MYRF

Across TCGA pan-cancer cohorts, MYRF RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated MYRF data layer compared with 9 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MYRF RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYRF expression acts as an unfavorable survival marker, although some lineages such as KIRC and SCLC show a favorable association.

ACC, LUAD, and KIRP are the cancer types where MYRF RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.165	0.682	<.001	88	view →
LUAD	DFS	Quartile	II,III,IV	0.385	0.584	<.001	75	view →
KIRP	OS	Tertile	All	0.592	0.839	<.001	70	view →
LUSC	DFS	Median	All	0.579	0.706	.004	53	view →
LIHC	DFS	Quartile	II,III,IV	0.152	0.408	.002	23	view →
UVM	DFS	Quartile	II,III,IV	0.314	0.680	.019	15	view →
COAD	OS	Tertile	IV	0.355	0.737	.004	14	view →
ESCA	OS	Median	All	0.617	1.000	.009	13	view →
PCPG	DFS	Quartile	All	0.743	0.965	.012	12	view →
KIRC	DFS	Median	IV	0.718	0.510	.016	10	view →
SCLC	DFS	Quartile	All	0.662	0.354	.014	10	view →
MESO	DFS	Quartile	IV	0.166	0.746	.006	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

MYRF–ACC (DFS)

Open the ACC breakdown →